BridgeBio Q2 revenue $243.7M, Attruby $222.4M; net loss $152.2M

BridgeBio Pharma, Inc.

Q2 total revenue $243.7M vs $110.6M YoY; US Attruby net product revenue $222.4M.
Net loss attributable to common stockholders $152.2M ($0.78/share) vs $181.9M ($0.95) year-ago.
Cash and marketable securities $720.2M at Jun 30; $1B preferred equity closed Jul 1 led by Sixth Street.
NDAs: BBP-418 PDUFA Nov 27 2026 (Priority Review), encaleret May 8 2027, infigratinib submitted.
Real-world data: acoramidis 37% reduction in composite CV events vs tafamidis (TriNetX, p=0.002).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.